Literature DB >> 18793253

Zoledronic acid for the treatment of appendicular osteosarcoma in a dog.

E P Spugnini1, B Vincenzi, G Caruso, A Baldi, G Citro, D Santini, G Tonini.   

Abstract

A 10-year-old male intact Corso dog was referred for lameness and for a large neoplasm affecting the right foreleg. Physical examination of the patient revealed a 5 x 5 x 3 cm mass in the distal right foreleg. Histopathology was consistent with a diagnosis of appendicular osteosarcoma. The staging process found no evidence of metastasis. Because of the large size of the patient, the owners elected to treat their dog with antiresorptive therapy. The patient was treated with an infusion of zoledronic acid every 28 days. The tumour remained stable for 16 months and the lameness of the dog greatly improved. At that time, the patient returned for evaluation of a large rapidly growing prescapular mass. Biopsy confirmed lymph node metastasis and the dog was euthanased. Zoledronic acid showed remarkable palliation in our patient and possibly anti-tumour action and warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18793253     DOI: 10.1111/j.1748-5827.2008.00635.x

Source DB:  PubMed          Journal:  J Small Anim Pract        ISSN: 0022-4510            Impact factor:   1.522


  7 in total

1.  Effect of zoledronic acid and amputation on bone invasion and lung metastasis of canine osteosarcoma in nude mice.

Authors:  Tobie D Wolfe; Smitha Pankajavally Somanathan Pillai; Blake Eason Hildreth; Lisa G Lanigan; Chelsea K Martin; Jillian L Werbeck; Thomas J Rosol
Journal:  Clin Exp Metastasis       Date:  2011-03-04       Impact factor: 5.150

2.  Retrospective Evaluation of Outcome in Dogs With Appendicular Osteosarcoma Following Hypofractionated Palliative Radiation Therapy With or Without Bisphosphonates: 165 Cases (2010-2019).

Authors:  Beck Ringdahl-Mayland; Douglas H Thamm; Tiffany W Martin
Journal:  Front Vet Sci       Date:  2022-05-10

3.  Toxicity of zoledronic acid after intravenous administration: A retrospective study of 95 dogs.

Authors:  David John Brewer; Michael Macfarlane; Erin O'Connell; Nicholas J Bacon
Journal:  J Vet Intern Med       Date:  2021-12-03       Impact factor: 3.333

4.  Combination Therapy with Zoledronic Acid and Parathyroid Hormone Improves Bone Architecture and Strength following a Clinically-Relevant Dose of Stereotactic Radiation Therapy for the Local Treatment of Canine Osteosarcoma in Athymic Rats.

Authors:  Ryan C Curtis; James T Custis; Nicole P Ehrhart; E J Ehrhart; Keith W Condon; Sara E Gookin; Seth W Donahue
Journal:  PLoS One       Date:  2016-06-22       Impact factor: 3.240

5.  Downregulation of CXCR4 Expression and Functionality After Zoledronate Exposure in Canine Osteosarcoma.

Authors:  M L Byrum; H C Pondenis; R L Fredrickson; K L Wycislo; T M Fan
Journal:  J Vet Intern Med       Date:  2016-06-02       Impact factor: 3.333

Review 6.  Bisphosphonate conjugation for bone specific drug targeting.

Authors:  Kristen B Farrell; Alexander Karpeisky; Douglas H Thamm; Shawn Zinnen
Journal:  Bone Rep       Date:  2018-07-03

7.  Medication-related osteonecrosis of the jaw after long-term bisphosphonate treatment in a cat.

Authors:  Melinda J Larson; Ashley B Oakes; Ember Epperson; Dennis J Chew
Journal:  J Vet Intern Med       Date:  2019-01-21       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.